/ CEU Credits:NaN

---

Description

Review the impact of Congenital CMV as the #1 cause of non-genetic deafness in newborns. The current testing algorithms, the different sample types and their advantages and disadvantages. Understand the legislations now in place addressing Congenital CMV testing. The majority of CMV positive babies are born asymptomatic, unless tested directly for the virus the Congenital CMV infection can be missed. Relying on newborn hearing screen is not sufficient to detect them all, given that 43% of CMV positive babies will pass their hearing test. Now there is an easy alternative to testing all babies for potential Congenital CMV infection. Alethia™ CMV from Meridian Bioscience, is the first FDA cleared saliva based molecular test for the detection of Congenital CMV in newborns <21 days. This simple molecular test provides accurate results in < 1 hr from an easy to collect saliva swab sample.

---

Tracks:

• 
  Lecture Series

---

Learning Objectives

• Have a deeper understanding of the impact of Congenital CMV has on newborns, the current practices and the legislations driving Congenital CMV testing.
• Bring back knowledge and educate their institution on the need and importance of Congenital CMV testing
• Know and understand the new alternative for Congenital CMV routine testing